Datrix (BIT:DATA)
Historical Stock Chart
From Jul 2019 to Jul 2024
![Click Here for more Datrix Charts. Click Here for more Datrix Charts.](/p.php?pid=staticchart&s=BIT%5EDATA&p=8&t=15)
DATATRAK Highlighted at SAS Users Group International as a
Leading EDC Provider
Participants get firsthand demonstration of the benefits in linking DATATRAK
EDC(R) and SAS Drug Development
CLEVELAND, April 11 /PRNewswire-FirstCall/ -- DATATRAK International, Inc.
(Nasdaq: "DATA"), the leading and most experienced Application Service Provider
(ASP) in the Electronic Data Capture (EDC) industry, today announced that the
Company has been highlighted as a leading EDC provider in an announcement
addressing the 30th Annual SAS Users Group International ("SUGI") meeting held
in Philadelphia, with attendance by more than 3,000 SAS users from around the
world.
As detailed in a separate announcement located on the SAS website at
http://www.sas.com/, nearly a dozen firms have turned to SAS Drug Development
for superior data warehousing, analytic, reporting and exploring technologies
that help turn vast amounts of data into the kind of intelligence demanded by
decision makers who need to respond quickly with the right decisions.
This announcement from SAS is significant for several reasons. It identifies
leading pharmaceutical companies who have elected to pursue SAS Drug
Development as a corporate strategy for clinical trials information processing.
Momentum for SAS Drug Development is clearly building, and more life sciences
firms will soon pursue SAS Drug Development as a strategy that solves many
internal process issues and makes information transfer and management more
efficient. Firms already using SAS software in their organizations include
every FORTUNE Global 500(R) Life Sciences Company and nearly 600 pharmaceutical
companies and divisions worldwide.
SAS Drug Development is linked directly to DATATRAK EDC(R) in order to provide
heretofore unavailable efficiencies in clinical data collection, surveillance
and management. There are two ways in which "DATATRAK Aware -- Powered by SAS"
can be purchased by clients. Any client can receive all the advantages of EDC
linked directly with SAS Drug Development on a trial-by-trial basis through an
incremental data item fee following the standard DATATRAK business model. In
this situation, no enterprise license of SAS Drug Development is required by
the clinical trial sponsor and no capital is required upfront. This approach
accommodates companies of any size, provides complete flexibility, and can be
activated at will.
Alternatively, customers who have already purchased SAS Drug Development can
further streamline their clinical trials operations by taking advantage of the
direct link to EDC. At that point, all that is required is a connection between
DATATRAK EDC(R) and the resources already devoted to SAS Drug Development. For
customers who have already purchased an enterprise SAS Drug Development
license, the incremental data item fee is waived. These customers can
immediately magnify the total value of SAS Drug Development because their
global clinical trials data is fed directly into their repository from an
automatic link with EDC that has already been prepared by DATATRAK and SAS.
"We are currently in dialogue with many different clients regarding the Aware
offering that fit within both implementation categories," stated Dr. Jeffrey A.
Green, President and Chief Executive Officer of DATATRAK International, Inc.
"Our co-marketing efforts with SAS have identified clients who use EDC and
desire a repository strategy, as well as clients who have purchased SAS Drug
Development and are attracted to the potential of direct linkages with EDC in
order leverage an investment and strategic direction they have already elected.
The ability to offer analyzable SAS datasets updated automatically as often as
every 24 hours and available through a thin client anywhere in the world
enables the closest to the maximum efficiency for this industry that one can
imagine."
About SAS
SAS is the market leader in providing a new generation of business intelligence
software and services that create true enterprise intelligence. SAS solutions
are used at more than 40,000 sites -- including 96 of the top 100 companies on
the FORTUNE Global 500(R) -- to develop more profitable relationships with
customers and suppliers; to enable better, more accurate and informed
decisions; and to drive organizations forward. SAS is the only vendor that
completely integrates leading data warehousing, analytics and traditional BI
applications to create intelligence from massive amounts of data. For nearly
three decades, SAS has been giving customers around the world The Power to
Know(R). Visit us at http://www.sas.com/.
About DATATRAK International
DATATRAK International, Inc. is a worldwide ASP for the EDC industry. The
Company provides a suite of software products supporting the use of DATATRAK
EDC(R) and related services to the pharmaceutical, biotechnology, and medical
device industries. DATATRAK EDC(R) was developed in order to deliver clinical
research data from investigative sites to clinical trial sponsors faster and
more efficiently than conventional, manual methods. DATATRAK EDC(R) can be
deployed worldwide in either a distributed platform using laptop computers or
in a centralized environment using the Internet. DATATRAK EDC(R) software and
its earlier versions have successfully supported many international clinical
studies involving thousands of clinical research sites and encompassing tens of
thousands of patients in over 46 countries. DATATRAK International, Inc.'s
product suite has been utilized in some aspect of the clinical development of
14 separate drugs that have received regulatory approval from either the United
States Food and Drug Administration or counterpart European bodies. DATATRAK
International, Inc. has offices located in Cleveland, Ohio and Bonn, Germany.
Its common stock is listed on the Nasdaq Stock Market under the symbol "DATA."
Visit the DATATRAK International, Inc. web site at http://www.datatrak.net/ or
http://www.datatraknet.de/.
Except for the historical information contained in this press release, the
statements made in this release are forward-looking statements. Factors that
may cause actual results to differ materially from those in the forward-looking
statements include the ability of the Company to absorb corporate overhead and
other fixed costs in order to successfully market the DATATRAK EDCO software;
the development and fluctuations in the market for EDC technology; continued
unreliability of the Internet infrastructure; the degree of the Company's
success in obtaining new contracts; the timing of payments from customers and
the timing of clinical trial sponsor decisions to conduct new clinical trials
or cancel or delay ongoing trials; dependence on key personnel; governmental
regulation; the early stage of the Company's EDC business and operations; and
general economic conditions. In addition, the Company's success depends on the
outcome of various strategic initiatives it has undertaken, all of which are
based on assumptions made by the Company concerning trends in the clinical
research market and the health care industry.
DATASOURCE: DATATRAK International, Inc.
CONTACT: Jeffrey A. Green, Pharm.D., FCP, President and Chief Executive
Officer, +1-440-443-0082, ext. 112, or Terry C. Black, Chief Financial
Officer, +1-440-443-0082, ext. 110, both of DATATRAK International, Inc.; or
Neal Feagans, Investor Relations of Feagans Consulting, Inc., +1-303-449-1184,
for DATATRAK International, Inc.
Web site: http://www.datatraknet.com/
http://www.datatraknet.de/
http://www.sas.com/